



Linezolid and Methicillin-Resistant Coagulase Negative Staphylococci from Anterior Nares of Nigerian Tertiary School Students

By Abdu Abdulrasheed, Kemebradikumo Pondei & Lamikanra Adebayo

Niger Delta University

Abstract- Background: The carriage of Coagulase Negative Staphylococci in the anterior nares of subjects in the study environment has not been investigated before and this study is thus a reference study against which future studies can be compared. The isolates obtained were also tested against frequently used antibiotics as well as linezolid, an antibiotic which is of considerable importance in the treatment of Multidrug resistant staphylococci.

Methods: A total of 400 nasal swabs were collected from anterior nares of apparently healthy subjects aseptically using a sterile swab sticks. The antibiotic susceptibilities of isolates of *S. aureus* obtained against eight different antibiotics including Linezolid were determined using the disc-plate method.

Keywords: *coagulase-negative staphylococci; antibiotic susceptibility patterns; methicillin-resistant CoNS, linezolid-resistant CoNS, anterior nares, apparently healthy, reference study.*

GJMR-C Classification: NLMC Code: QW 161.5.S8



Strictly as per the compliance and regulations of:



Linezolid and Methicillin-Resistant Coagulase Negative Staphylococci from Anterior Nares of Nigerian Tertiary School Students

Abdu Abdulrasheed ^α, Kemebradikumo Pondei ^σ & Lamikanra Adebayo ^ρ

Abstract- Background: The carriage of Coagulase Negative Staphylococci in the anterior nares of subjects in the study environment has not been investigated before and this study is thus a reference study against which future studies can be compared. The isolates obtained were also tested against frequently used antibiotics as well as linezolid, an antibiotic which is of considerable importance in the treatment of Multidrug resistant staphylococci.

Methods: A total of 400 nasal swabs were collected from anterior nares of apparently healthy subjects aseptically using a sterile swab sticks. The antibiotic susceptibilities of isolates of *S. aureus* obtained against eight different antibiotics including Linezolid were determined using the disc-plate method.

Results: The results showed that 136(34.03%) of the subjects tested are nasal carriers of CoNS: *S. epidermidis* 50(36.76%) which is the most prevalent. This is followed by *S. haemolyticus* 41(30.15%), *S. saprophyticus* 13(9.56%), *S. hominis* 10(7.35%), *S. cohnii* 8(5.88%), while *S. lugdunensis* and *S. xylosus* were 7(5.15%) each. The incidences of resistance observed with each of the antibiotics tested were as follow: Erythromycin 112(82.4%), Tetracycline 108(79.4%), Co-trimoxazole 94(69.1%), Cefoxitin 80(58.8%), Linezolid 75(55.1%), Ciprofloxacin 66(48.5%), Augmentin 43(31.6%) and Gentamycin 31(22.8%).

Conclusion: Treatment of CoNS infections within the study environment should be based on the results of *in vitro* susceptibility testing of the isolates. Gentamicin and Augmentin promises to be the best antibiotic for the treatment of disorders associated with Staphylococci in the study area. This is of special importance in an environment within which a very substantial proportion of the isolates are resistant to methicillin and linezolid.

Keywords: coagulase-negative staphylococci; antibiotic susceptibility patterns; methicillin-resistant CoNS, linezolid-resistant CoNS, anterior nares, apparently healthy, reference study.

Author ^α: Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Amassoma, Bayelsa-State.
e-mail: abdu@soul@gmail.com

Author ^σ ^ρ: Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Amassoma, Bayelsa-State, Department of Pharmaceutics, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun-state.
e-mails: kemepondei@hotmail.com, adebayolamikanra@gmail.com

I. INTRODUCTION

Coagulase-negative staphylococci (CoNS) are part of normal commensals of the skin, anterior nares, and ear canals of humans [1]. Because of their relatively low virulence, they have long been considered as nonpathogenetic, and were rarely reported to cause severe infections. However, as a result of the combination of increased use of intravascular devices and an increase in the number of hospitalised immunocompromised patients, CoNS have emerged and are increasingly recognised as a major agents of clinically significant infection of the bloodstream and other sites [2, 3, 4, 5, 6, 7, 8].

Given the frequency with which multiple antimicrobial resistance is encountered, treatment of CoNS infections can be challenging and oxazolidinone: Linezolid has been considered the drug of choice for the management of infections caused by gram-positive organisms, including resistant organisms, such as methicillin-resistant *Staphylococcus aureus*, methicillin-resistant coagulase-negative staphylococci (MRCoNS), vancomycin-resistant enterococci, and multidrug-resistant *Streptococcus pneumoniae* [9, 10, 11, 12, 13, 14, 15]. However, widespread use of linezolid recently has led to the emergence of CoNS isolates with decreased susceptibility to these agents further limiting therapeutic options for treatment of infections caused by these organisms [16, 17, 18].

In Nigeria, to date, Linezolid-Resistant Coagulase Negative Staphylococcus (LRCoNS) have not been reported, although there are no indications of the use of linezolid within the study area, it is recognized as one of the few drugs that have been reported to be effective in the treatment of infections caused by MRCoNS. In the current study, we determined nasal carriage rate of CoNS and antimicrobial resistance profile of these coagulase-negative staphylococci isolates with linezolid resistance that were recovered from apparently healthy undergraduate students in Niger Delta University. This study will however serve as a reference point data for nasal carriage rate and Linezolid antimicrobial profile of CoNS for the region.

II. MATERIALS AND METHODS

a) Sampling Area

The study was carried out in Amassoma, a semi urban settlement in the Niger Delta and is home to the Niger Delta University with a student population of about 20,000. It is located on Latitude 4° 59' 09" N and longitude 6° 06' 34" E. Its land area is 2,682Km² (1,036 sq miles) at an elevation/altitude of 9 metres. It is in an area of high humidity (mean: 300C) and temperature (average: 26.7°C with annual rainfall of about 1777mm).

The students sampled in this study were medical and nursing students of the university. They are of age: (range: 15-39, mean = 22), Sex: (Males: 124; Females: 276) and have stayed a period of 1 year minimum in the University

b) Sampling

Anterior nares swabs were collected in accord to protocols described by Rongpharpi *et al* [19]. A total of 400 nasal swabs were collected from anterior nares of apparently healthy subjects aseptically using a sterile swab sticks (Copan Diagnostics, Corona, CA, USA). Swabs were transported in Amies (Oxoid, England) transport medium to the Medical microbiology laboratory of the College of Health Sciences, Niger Delta University for bacteriological assay.

c) Isolation and Identification

In the laboratory, each swab was immediately inoculated onto Mannitol Salt Agar (MSA; Oxoid, England) plates and incubated at 37C for 24 h. The characteristic isolates were aseptically isolated and characterized using established microbiological methods that include colonial morphology, Gram stain characteristics, haemolysin production catalase, coagulase tests as well as DNase production [20]. The various isolates were identified to species level by employing standard microbiological methods [20, 21]. Coagulase negative-Staphylococci isolates were confirmed through the use of the Staph identification 25 E (BioMeriux, France).

d) Antimicrobial Susceptibility Testing

The antimicrobial susceptibility pattern of all the isolates to Augmentin (30µg), Cefoxitin (30µg), Ciprofloxacin (5µg), Co-trimoxazole (25µg), Erythromycin (15µg), Gentamycin (30µg), Linezolid (30µg), and Tetracycline (30µg) all obtained from Oxoid (England) were determined using modified single disc diffusion technique in accordance to the guidelines of Clinical and Laboratory Standards Institute (CLSI, 2012) [22]. Briefly, standardized overnight culture of each isolate (containing approximately 10⁶ cfu/ml) which was equivalent to 0.5 McFarland Standard was used to swab the surface of Mueller Hinton agar plates and excess drained off and dried while the Petri dish lid was in place. The standard antimicrobial discs were aseptically

placed at reasonable equidistance on the inoculated plates and allowed to stand for 1 hr. The plates (prepared in duplicates) were then incubated at 37°C for 18-24 h. The diameter of the zone of inhibition produced by each antimicrobial disc was measured with a ruler in millimeters. Breakpoints and interpretative for susceptibility/resistance was based on the CSLI criteria [22]. We used the agar dilution method to further confirm the Linezolid MIC's (lowest concentration at which growth was inhibited) values of the linezolid-nonsusceptible CoNS isolates. The MIC (µg/mL) interpretative standard for linezolid were those suggested by CLSI [22], (respectively: ≤ 4 susceptible, ≥ 8 resistant). The procedure was performed in duplicate on separate occasions, and the means of the duplicates were used. *Staphylococcus aureus* NCTC6571 was used as the quality control in each set of tests.

e) Statistical analysis

SPSS for Windows (version 20.0; SPSS) software was used for the analysis. Frequency distribution, mean, harmonic mean, standard deviation, analysis of variance (ANOVA) were determined. Categorical variables were compared by using Pearson's chi-squared test (χ^2) or Fisher's exact probability tests. P-values were calculated and $P \leq 0.05$ was considered statistically significant

III. RESULTS

As depicted in Table 1, 227(56.8%) of the 400 studied subjects yielded Staphylococci growths. The overall carriage rates of Coagulase Negative *Staphylococci* was 136(34.03%).

As shown in Figure 1, we identified and confirmed that the 136 CoNS strains belong to 7 species including *S. epidermidis* 50(36.76%) which is the most prevalent. This is followed by *S. haemolyticus* 41(30.15%), *S. saprophyticus* 13(9.56%), *S. hominis* 10(7.35%), *S. cohnii* 8(5.88%), while *Staphylococcus lugdunensis* and *S. xylosus* were 7(5.15%) each.

Figure 2, shows the antimicrobial susceptibility profile of the isolates. Overall 112(82.4%) of the 136 CoNS isolates showed resistance to Erythromycin, while resistance were 108(79.4), 94(69.1%), 80(58.8%), 75(55.1%), 66(48.5%), 43(31.6%) and 31(22.8%) to Tetracycline, Co-trimoxazole, Cefoxitin [MRCoNS], Ciprofloxacin, Linezolid, Augmentin, and Gentamycin respectively

The prevalence of multiple antibiotic resistance (MAR) of the isolates was investigated. One hundred and twelve (82.35%) of the isolates showed multiple resistance in varying degrees. Twenty-three (20.54%), 18 (16.07%), 26(23.21%), 22(19.64%), and 10 (8.93%) were resistant to 3, 4, 5, 6, and 7 antibiotics among the isolated strains respectively. Thirteen (11.61%) of the

isolates were resistant to all the 8 antibiotics tested (Figure 3).

IV. DISCUSSION

We conducted this study in order to determine the nasal carriage rate and antimicrobial resistance profile of CoNS strains isolated from the anterior nares of apparently healthy students of a tertiary institution in Wilberforce Island, Amassoma. The institution is situated in a semi urban area in Bayelsa-state in the Niger Delta. The result obtained from the present study will serve as a reference data for CoNS carriage rate. In addition, the study also gives an understanding into the patterns of antimicrobial resistance profile of these isolates in the locality.

The study revealed that 136 out of the 400 subjects examined were positive for CoNS in their anterior nares, indicating the nasal carriage rate of 34.03%. Earlier, report indicates the nasal carriage rate of CoNS to vary from 13% to 56% in different populations [13, 23, 24, 25]. Though we observed lower figure in the present study, our findings is in comparison with the carriage rates documented by Morgenstern et al. [26] and Lebeaux et al. [27] in Portugal and France respectively. Contrast with our findings, higher nasal carriage rates have however been reported by Koziol-Montewka *et al.*, 2006 in Poland (55.8%) [28], Campeotto *et al.* 2004 in Brazil (66.1%) [29], Akhtar 2010 inPakistan (73.3%) [30] and Abadi et al. 2015 in Iran (77.7%) [31]. Shibabaw et al. [32] attributed these differences to various microbiological methods (sampling techniques to culture media) employed, the local infection control standards and the local prevalence rate. Aside from these, it has been suggested that carrier rates might also be influenced by poor personal hygiene, poor environmental sanitation [32] and age-related dynamics of the study participants [1]. The low recovery rate of CoNS observed in the present study might be due to the fact that our subjects being medical and nursing students may have been involved in good hygiene practices with hand washing inclusive. On the other hand, as documented by Onasoga, et al., 2015 [33], they may have also been involved in self-medication or predisposed to the misuse of antibiotics.

The results showed that seven species of CoNS were identified. The most common species isolated was *S. epidermidis* 50(36.76%). The similar results were recorded in many studies [34]. Various studies have indicated most CoNS isolates obtained in the present study as responsible for infections that are of endogenous origin particularly among immunocompromised and individuals that are hospitalized [35, 36, 37, 38, 39, 40].

Over the years, studies have shown that antimicrobial therapy causes marked symptom

improvement and shortens the duration of illness associated with *Staphylococci* infections. Before now, various types of antimicrobial agents have been efficacious in the management of *Staphylococci* infections, but options for treatment of these diseases are becoming restricted due to the appearance of multidrug-resistant strains of CoNS. There has been global concern about the emergence of antimicrobial resistance in common pathogens of community as well as nosocomial infections and CoNS have demonstrated a pattern of progressively increasing resistance to antibiotics worldwide [41, 42, 43, 44, 45, 46, 47, 48]. The results obtained from the present study indicates that 112(82.35%) of the 136 isolates from this environment are multiply resistant to antibiotics, (Figure 3). In comparison, the pattern of multidrug resistance demonstrated here has been described among CoNS isolates in different part of the world which includes Switzerland [26], India [49], Iran [31, 34], China [44], USA [50], France [27], Pakistan [30], Italy [51] and Poland [28].

The antibiotic susceptibility pattern of the isolates shows that Gentamycin was the most effective among the CoNS, followed by augmentin, in that order (Figure 2). When compared with existing report, the 22.8% resistance of the CoNS isolates to Gentamycin in this finding corroborates the report of Ma *et al.* [48] and is different with report of Al-Muhanna *et al.* [34] that 32% of CoNS isolates were resistant to Gentamycin, while Roopa and Biradar [49] and Zhanel *et al.* [52] reported 0.0% and 78.8% resistance of these pathogens to Gentamycin respectively. So gentamycin is the only drug in this study that is proven to be effective for CoNS. One of the reason for this high susceptibility seen in this study may be that gentamycin appears to be infrequently used as it administered by injection, a dosage form which is far less amenable to self-medication than orally administered antibiotics in this locality[53].

On the other hand, the high susceptibility to augmentin observed in this study is in sharp contrast to existing reports (31.6% versus 70%; $P < 0.0001$) by Abdalla *et al.* [54] and Akinkunmi and Lamikanra [55] that 70% and 62.4% resistance of CoNS to augmentin respectively. Nonetheless, the present findings corroborates the report of Roopa and Biradar [49]. One of the reason that could be adduced to low resistance observed in this study may be that augmentin, though an orally administered antibiotics, seems to be rarely abused by individuals in the locality because of its exorbitant price (about 10USD) for a packet in a locality where people live below 1USD per day.

The antimicrobial resistance profile of CoNS isolated in this study indicated that 58.8% of the isolates were resistant to Cefoxitin [MR-CoNS]. This result is higher than earlier report [49, 55], and, lower than report made by Al-Muhanna *et al.*, [34], Maet *al.* [48] and

Koksal *et al* [56]. However, it is similar to the report made by Lebeaux *et al.* [27] among the organisms isolated in their respective studies. Reports have documented that resistance to Cefoxitin by disc diffusion can be used for the detection of MRSA strains in routine testing [57] because Cefoxitin is regarded as a potential inducer of the system that regulates *mecA gene*[58]. For this reason, the resistant of our isolates which were found to be resistant to Cefoxitin are considered resistant to methicillin (58.8% MR-CoNS).

During the susceptibility test in the present study, one of our limitations was excluding Vancomycin, the drug considered efficacious for MRSA and MRCoNS, from the test because of unavailability of its commercial disc. Nonetheless, Delorme *et al.*[59] reported the exclusion of vancomycin from their study because vancomycin may produce erratic results in disc diffusion susceptibility test [59]. However, even with the absence of vancomycin susceptibility test, the result of this study can be compared with the findings of several outcomes including [60, 61, 62, 63] which established that linezolid is a drug that is as effective as vancomycin. Both antibiotics do not just have similar failure and success rates but adverse effects as well [61, 64].

Approximately, 69.1% of the CoNS isolates showed high resistance to trimethoprim/sulfamethoxazole in this study. This is similar to what has been reported by Koksal *et al.* [56] and Akinkunmi and Lamikanra [55] in Turkey and Ile-Ife, Nigeria respectively and many other researchers, a finding correlated to that by Ma *et al* [48] and Abadi *et al.* [31]. This could be due to the fact that this drug is very commonly available in our setting and is also indiscriminately used for prophylaxis by individuals with symptoms of Upper Respiratory Tract infections (URTI) and Urinary Tract Infections (UTI). The study by Paul *et al.*[65] showed zero resistance to trimethoprim/sulfamethoxazole to *Staphylococcus aureus* in Nigeria in 1985, while Gu *et al.*[10] showed 29.4% trimethoprim/sulfamethoxazole in Greece. This is worthy of mention and comparison. It shows that trimethoprim/sulfamethoxazole resistance has increased prodigiously over the prevailing years.

The majority of our CoNS isolates were highly resistant to erythromycin (82.4%), and the high rate (79.4%) of resistant to tetracycline and Ciprofloxacin (55.1%), found in this study is worrisome considering the ability of these organisms to spread easily by direct or indirect person-to-person contact with resultant therapeutic complications and considering that ciprofloxacin has been identified as the drug being the most efficacious anti-infective drug in Nigeria [43, 66].

Combating the increase in mortality and morbidity due to therapeutic failures in the treatment of multidrug resistant Staphylococci infections, particularly those that are methicillin and vancomycin resistances, gave rise to the need for newer efficacious therapeutic

options leads to the discovery and approval of oxazolidinone antibiotic: linezolid by FDA in 2000 as an attractive alternative to vancomycin and MRSA [60, 67]. It is tragic that barely one year of its introduction into treatment regime for multidrug resistant Gram-positive organisms, the first resistant among *Enterococcus faecium*, was reported [68] and Tsiodras *et al.* [69] reported the first Linezolid resistant *Staphylococcus aureus* in a US patient. Since then, linezolid-resistant *S. aureus* and CoNS have been detected in separate cases and outbreaks worldwide [10, 70, 71].

Currently, 48.5% of CoNS isolated from the present study were found to be linezolid resistant. Making this finding one of the highest resistance rate recovered among CoNS isolates in Nigeria and amongst those recorded globally. This study revealed that *S. epidermidis*, *S. haemolyticus*, *S. cohnii*, *S. saprophyticus*, *S. hominis* isolates, were resistant to linezolid in 52%, 50%, 48.78%, 46.15%, and 40% respectively, while *S. lugdunensis* and *S. xylosus* showed 42.86% resistance to linezolid each (Table 2). To confirm this resistivity, we decided to carry out Minimum Inhibitory Concentration tests on these isolates as suggested by CLSI 2012 [22], and the outcome showed that all our linezolid resistant isolates had MICs >256µg/mL.

Previous studies have shown various resistance profiles of CoNS to linezolid. For example, Morgenstern *et al.* [26] in Switzerland and [44] in China reported 0% resistance to linezolid respectively. However, globally, surveillance studies report <1% of CoNS as linezolid resistant. But, a study conducted by Potoski *et al.*[72] in the USA, observed Linezolid resistance in about 4.0% of MRCoNS isolates. Another study conducted in USA by Helio and colleagues reported LRCoNS in 0.1% [50]. Similarly, incidence of 0% was reported by Al-Muhanna *et al.* [34] from Iraq. Ugwuet *al.*[66] reported 0% LRCoNS in Southern Nigeria. The high incidence of linezolid resistance in the organisms isolated in this study is not expected since this antibiotic is not broadly used within the study environment, this is worrisome and is worthy of note. Particularly that linezolid is not routinely prescribed and administered in our locality. More so that the drug is very difficult, if available in our market, in other words, its availability for misuse or self-administration as reported among other antibiotics is not anticipated [73]. So, this high resistance recorded must be of concern to practitioners and public health, more so, that these organisms live in association with other organisms in their ecological niche and can disseminate these resistances to other organisms within the environment [73]. This collaborates reports made by Garcia *et al.* [74] that horizontal transmission of linezolid resistance could pose a serious threat, because the *cfr gene* can also be transmitted between species, such as from *S. epidermidis*, which although not pathogenic, could become a reservoir for resistance genes and that

this mode of transmission becomes more difficult to prevent and stop than those of nosocomial spread that are usually controlled with standard measures, such as isolation, barrier precautions, and antibiotic restriction. On the other hand, these organisms and their antimicrobial resistance have been documented to be associated with opportunistic infections and can be transferred from these individuals to the patients, hospital environments and the community [41, 75, 76] making it a life-threatening organism which may lead to increase mortality and morbidity, particularly among colonised individuals, immunocompromised and HIV patients. Staphylococcal resistance to linezolid (LZD) is said to be mediated through ribosomal mutations (23S rRNA or ribosomal proteins L3 and L4) or through methylation of 23S rRNA by the horizontally transferred *chloramphenicol-florfenicol resistance (Cfr)* plasmid-borne ribosomal methyltransferase that catalyzes methylation of A2503 in the 23S rRNA gene of the large 50S ribosomal subunit, conferring resistance to chloramphenicol, florfenicol, and clindamycin [9, 77, 78, 79, 80, 81, 82]. The first *cfr*-mediated, linezolid-resistant clinical isolate of MRSA was reported in 2007 by Tohet *et al.* [83]. More recently, linezolid resistance has been identified due to acquisition of a natural resistance gene, *cfr*, so the high resistance of the present study CoNS isolates to linezolid might be due to acquisition of resistance to chloramphenicol, as chloramphenicol is one of the antibiotics that are readily available and most abuse, misuse and self-medicated in our locality. However, this assumption would be further investigated.

V. CONCLUSION

The study findings indicate the usefulness of investigation of CoNS colonisation of the nasal mucosa the primary ecological niche for these microorganisms in order to better understand the epidemiology of this phenomenon, but also to develop prevention measures and treatment strategies in case of established infections among predisposed individuals.

VI. ACKNOWLEDGEMENTS

We are grateful to Ogobiri Gloria Tamaraemomoemi, Tiemo, and Pereyan Cynthia for Collection of the samples and the school students for participating in this study.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev* 2014; 27: 870.
2. Zong ZY, Peng CH, Lu X.J. Diversity of SCCmec elements in methicillin-resistant coagulase-negative staphylococci clinical isolates. *PLoS One* 2011, 6: e20191.
3. Dubois D, Leyssene D, Chacornac JP, Kostrzewa M, Schmit PO, Talon R, Bonnet R, Delmas J.

Identification of a variety of Staphylococcus species by matrix-assisted laser desorption ionization time of flight mass spectrometry. *J Clin Microbiol* 2010, 48: 941–945.

4. Cervera C, Almela M, Martinez-Martinez JA, Moreno A, Miro JM. Risk factors and management of Gram-positive bacteraemia. *Int. J. Antimicrob. Agents* 2009, 34(Suppl. 4): S26–S30.
5. Otto M. *Staphylococcus epidermidis* – the ‘accidental’ pathogen. *Nat Rev Microbiol* 2009, 7: 555–56.
6. Rogers KL, Fey PD, Rupp ME. Coagulase-negative staphylococcal infections. *Infect Dis Clin North Am* 2009, 23(1): 73-98.
7. Casey AL, Lambert PA, Elliott TSJ. Staphylococci. *Int J Antimicrob Agents* 2007, 29 (Suppl. 3): S23–S32.
8. Emory TG, Gaynes RP: An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin Microbiol Rev* 1993, 6: 428-442.
9. Tewhey R, Gu B, Kelesidis T, Charlton C, Bobenchik A, Hindler J, Schork NJ, *et al.* Mechanisms of Linezolid Resistance among Coagulase-Negative Staphylococci Determined by Whole-Genome Sequencing. *mBio* 2014, 5(3): e00894-14. doi:10.1128/mBio.00894-14.
10. Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J. & Humphries, R. M. (2013). The emerging problem of linezolid-resistant Staphylococcus. *J Antimicrob Chemother* 68, 4–11.
11. Farrell DJ, Mendes RE, Ross JE *et al.* LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. *Antimicrob Agents Chemother* 2011; 55: 3684 –90.
12. Ross JE, Farrell DJ, Mendes RE *et al.* Eight-year (2002–2009) summary of the linezolid (Zyvox(R) Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. *J Chemother* 2011; 23: 71–6.
13. Hill RL, Kearns AM, Nash J *et al.* Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. *J Antimicrob Chemother* 2010; 65: 442–5.
14. Hong T, Li X, Wang J, Sloan C, Cicogna C. Sequential Linezolid-Resistant Staphylococcus epidermidis Isolates with G2576T Mutation^Y. *J Clin Microbiol* 2007, 45(10): 3277–3280.
15. Diekema DJ, Jones RN. Oxazolidinone antibiotics. *Lancet* 2001; 358:1975–82
16. Sanchez Garcia M, De la Torre MA, Morales G *et al.* Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. *JAMA* 2010; 303: 2260–4.
17. Mendes RE, Deshpande LM, Farrell DJ *et al.* Assessment of linezolid resistance mechanisms

- among *Staphylococcus epidermidis* causing bacteraemia in Rome, Italy. *J Antimicrob Chemother* 2010; 65: 2329–35.
18. Tegnell A, Grabowska K, Jacobsson A, Andersson M, Giesecke J, Ohman L. 2003. Study of developed resistance due to antibiotic treatment of coagulase-negative staphylococci. *Microb Drug Resist* 9: 1–6.
 19. Rongpharpi SR, Hazarika NK, Kalita H. The prevalence of nasal carriage of *Staphylococcus aureus* among healthcare workers at a tertiary care hospital in Assam with special reference to MRSA. *J Clin. Diagn Res.* 2013; 7(2): 257-60.
 20. Cheesbrough M. District laboratory practice in tropical countries Part 2: Edinburgh building. Cambridge University Press. UK. 2002; 136-2.
 21. Cowan ST, Steel KJ. Manual for the identification of medical Bacteria. 3rd edition. Barrow GI, Feltham RKA, editors. Cambridge University Press. 2004; 55-9.
 22. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Eighteenth Information Supplement. 2012; 28(1): 34-52.
 23. Ternes YM, Lamaro-Cardoso J, André MCP, Pessoa Jr. VP, Vieira MAS, Minamisava R, Andrade AL, Kipnis A. Molecular epidemiology of coagulase-negative *Staphylococcus* carriage in neonates admitted to an intensive care unit in Brazil. *BMC Infectious Diseases* 2013, 13: 572.
 24. Bjorkqvist M, Liljedahl M, Zimmermann J, Schollin J, Soderquist B: Colonization pattern of coagulase-negative staphylococci in preterm neonates and the relation to bacteremia. *Eur J Clin Microbiol Infect Dis* 2010, 29(9): 1085–1093.
 25. Jamaluddin TZ, Kuwahara-Arai K, Hisata K, Terasawa M, Cui L, Baba T, Sotozono C, Kinoshita S, Ito T, Hiramatsu K: Extreme genetic diversity of methicillin-resistant *Staphylococcus epidermidis* strains disseminated among healthy Japanese children. *J Clin Microbiol* 2008, 46(11): 3778–3783.
 26. Morgenstern M, Erichsen C, Hackl S, Mily J, Militz M, Friederichs J, et al. (2016) Antibiotic Resistance of Commensal *Staphylococcus aureus* and Coagulase-Negative Staphylococci in an International Cohort of Surgeons: A Prospective Point-Prevalence Study. *PLoS ONE* 11(2): e0148437. doi:10.1371/journal.pone.0148437
 27. Lebeaux D, Barbier F, Angebault C, Benmahdi L, Ruppé E, Benjamin Felix B et al. Evolution of Nasal Carriage of Methicillin-Resistant Coagulase-Negative Staphylococci in a Remote Population. *Antimicrob Agents and Chemother* 2012, 56(1): 315–23.
 28. Koziol-Montewka M, Szczepanik A, Baranowicz I, Jo´z´wiak L, Ksia´ z´ek A, Kaczor D. The investigation of *Staphylococcus aureus* and coagulase-negative staphylococci nasal carriage among patients undergoing haemodialysis. *Microbiol Res* 2006, 161: 281-7.
 29. Campeotto F, Garnier F, Kalach N, Soulaines P, Dupont C, Raymond J: A routine prospective survey process to detect nosocomial bacterial colonization in a neonatal unit: risk factors for acquisition. *Arch Pediatr* 2004, 11(11): 1314–1318.
 30. Akhtar N. Staphylococcal Nasal Carriage of Health Care Workers *J Coll Physicians Surg Pak* 2010, 20 (7): 439-443.
 31. Abadi MIM, Moniri R, Khorshidi A, Piroozmand A, Mousavi SGA, Dastehgoli K; Ghazikalaye HM. Molecular Characteristics of Nasal Carriage Methicillin-Resistant Coagulase Negative Staphylococci in School Students. *Jundishapur J Microbiol.* 2015, 8(6): e18591.
 32. Shibabaw A, Abebe T, Mihret A. Antimicrobial susceptibility pattern of nasal *Staphylococcus aureus* among dessie referral hospital health care workers, dessie, Northeast Ethiopia. *Int J. Infect Dis.* 2014; 25: 22-5.
 33. Onasoga, OA, Abdu A, Anabui BN, Hanson VF. Pattern and management of sexually transmitted infections (STIs) among undergraduates attending university health care centre in Bayelsa State, Nigeria. *Int STD Res Rev.* 2015; 3(3): 137-146.
 34. Al- Muhanna AS, Al-Hilu SA, Alzuhairi MA. Characterization of coagulase-negative, oxacillin resistant staphylococci from patients undergoing catheter related infections. *Eur J Exp Biol.* 2014, 4(3): 774-78.
 35. Danzmann L, Gastmeier P, Schwab F, Vonberg RP. Health care workers causing large nosocomial outbreaks: a systematic review. *BMC Infect Dis.* 2013; 13:98. doi: 10.1186/1471-2334-13-98 PMID: 23432927; PubMed Central PMCID: PMC3599984.
 36. Miragaia M, Thomas JC, Couto I, Enright MC, de Lencastre H: Inferring a population structure for *Staphylococcus epidermidis* from multilocus sequence typing data. *J Bacteriol* 2007, 189(6): 2540–2552.
 37. Becker K, Heilmann C, Peters G. Coagulase-Negative Staphylococci. *Clin Microbiol Rev* 2014, 27(4): 870-926.
 38. Heikens E, Fler A, Paauw A, Florijn A, Fluit AC. Comparison of genotypic and phenotypic methods for species-level identification of clinical isolates of coagulase-negative staphylococci. *J Clin Microbiol.* 2005; 43(5): 2286–90.
 39. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control.* 2004; 32(8): 470–85. doi: 10.1016/j.ajic.2004.10.001 PMID: 1557 3054.

40. de Mattos EM, Teixeira LA, Alves VM, Rezenda e Resende CA, da Silva Coimbra MV, da Silva-Carvalho MC, Ferreira-Carvalho BT, Figueiredo AM: Isolation of methicillin-resistant coagulase-negative staphylococci from patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and comparison of different molecular techniques for discriminating isolates of *Staphylococcus epidermidis*. *Diagn Microbiol Infect Dis* 2003, 45(1): 13–22.
41. Hammuel C, Idoko MO, Migap HH, Ambrose N. Occurrence and antibiogram profile of *Staphylococcus aureus* isolated from some hospital environment in Zaria, Nigeria. *Afr J Microbiol Res*. 2015; 9(19): 1304-11.
42. Hammuel C, Jatau DE, Whong CMZ. Prevalence and antibiogram pattern of some nosocomial pathogens isolated from hospital environment in Zaria, Nigeria. *Aceh Int. J. Sci. Technol.* 2014; 3(3): 131-9.
43. Babafemi EO, David OM, Oluduro AO, Famurewa O. Epidemiology of methicillin-resistant *Staphylococcus aureus* among hospitalized patients and apparently healthy individuals in Ekiti and Ondo States, Nigeria. *J Pharm Biomed Sci*. 2014; 4(11): 1125-30
44. Wei L, Wu R, Zou F, Liu G, Wu L, Wei Q, Li J, Lei L, Duo, H. Antibiotic resistance pattern of methicillin-resistance and coagulase-negative *Staphylococcus* isolates among hospitalized patients at a tertiary hospital in Gansu, North-western China. *Afr. J. Microbiol. Res* 2014, 8(1): 105-108.
45. Oli AN, Nweke JN, Ugw MC, Anagu LO, Oli AH, Esimone CO. Knowledge and use of disinfection policy in some government hospitals in South-East, Nigeria. *Bri J. Med Medical Res*. 2013; 3(4): 1097-1108.
46. Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian S, Hujer AM, et al. Emergence of linezolid-resistant *Staphylococcus aureus* after prolonged treatment of cystic fibrosis patients in cleveland, Ohio. *Antimicrob. Agents Chemother*. 2011; 1684–1692.
47. Shittu AO, Okon K, Adesida S, Oyedara O, Witte W, Strommenger B, et al. Antibiotic resistance and molecular epidemiology of *Staphylococcus aureus* in Nigeria. *BMC Microbiol*. 2011; 11: 92. Available: <http://www.biomedcentral.com/1471-2180/11/92>
48. Ma XX, Wang EH, Liu Y, Luo EJ. Antibiotic susceptibility of coagulase-negative staphylococci (CoNS): emergence of teicoplanin non-susceptible CoNS strains with inducible resistance to vancomycin. *J Med Microbiol* 2011, 60, 1661–68.
49. Roopa C. and Biradar S. Incidence and Speciation of Coagulase Negative *Staphylococcus* Isolates from Clinically Relevant Specimens with their Antibiotic Susceptibility Patterns. *Int. J. Curr. Microbiol. App. Sci* 2015; 4(9): 975-980.
50. Helio S. Sader, Robert K. Flamm, Ronald N. Jones. Antimicrobial Activity of Ceftaroline Tested against *Staphylococci* with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011. *Antimicrob Agents and Chemother* 2013, 57(7): 3178-81.
51. Bongiorno D, Campanile F, Mongelli G, Baldi MT, Provenzani R, Reali S et al. DNA methylase modifications and other linezolid resistance mutations in coagulase-negative staphylococci in Italy. *J Antimicrob Chemother* 2010; 65: 2336–40.
52. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuk AJ, Lagacé-Wiens P, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. *J. Antimicrob. Chemother.* 2013. 68(Suppl 1): i7–i22. <http://dx.doi.org/10.1093/jac/dkt022>
53. Onanuga A, Oyi AR, Olayinkayinka BO, Onaolapo JA. Prevalence of community-associated multi-resistant *Staphylococcus aureus* among healthy women in Abuja, Nigeria. *Afr. J. Biotech.* 2005; 4: 942-5.
54. Abdalla NM, Haimour WO, Osman AA, Sarhan MA, Musaa HA. Antibiotics Sensitivity Profile Towards *Staphylococcus hominis* in Assir Region of Saudi Arabia. *J. Sci. Res.* 2013, 5 (1): 171-183.
55. Akinkunmi EO, Lamikanra A. Species Distribution and Antibiotic Resistance in Coagulase-negative *Staphylococci* Colonizing the Gastrointestinal Tract of Children in Ile-Ife, Nigeria. *Trop J Pharm Res*, 2010; 9 (1): 35-43.
56. Koksall F, Yasar H, Samasti M. Antibiotic resistance patterns of coagulase-negative staphylococcus strains isolated from blood cultures of septicemic patients in Turkey. *Microbiol Res* 2009, 164: 404-10.
57. Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial susceptibility testing. Twenty-fourth Information Supplement. 2014; 34(1): M100-S24: 67-68
58. Madhusudhan NS, Deepa S, Shoba DN. Correlation of cefoxitin disc diffusion test and oxacillin disc diffusion test for detecting *mecA* mediated oxacillin resistant *Staphylococcus aureus*. *J. Pharm Biomed Sci*. 2011; 10(2):2230–7885.
59. Delorme T, Rose S, Senita J, Callahan C, Nasr P. Epidemiology and susceptibilities of methicillin-resistant *Staphylococcus aureus* in Northeastern Ohio. *The Am J Clin Pathol*. 2009; 132(5): 616–687.
60. Juayang AC, de los Reyes GB, de la Rama AJG, Gallega CT. Antibiotic resistance profiling of *Staphylococcus aureus* isolated from clinical specimens in a tertiary hospital from 2010 to 2012. *Interdiscip Perspect Infect Dis*. 2014; 2014:1-4. Available: <http://dx.doi.org/10.1155/2014/898457>



61. Pogue JM, Alaniz C. Vancomycin versus linezolid in the treatment of methicillin resistant *Staphylococcus aureus* nosocomial pneumonia: Implications of the ZEPHYR trial. *Ann Pharmacother.* 2012; 46(10): 1432–5.
62. Khan Z, Faisal S, Hasnain S. The continuing threat of methicillin resistant *Staphylococcus aureus*—past, present, future. *J Sci Res.* 2010; 40(2): 31–4
63. Guzmán-Blanco M, Mejía C, Isturiz R, Alvarez C, Bavestrello L, Gotuzzo E, Labarca J, Carlos M. Luna, Rodríguez-Noriega E, Salles MJC, Zurita J, Seas C. Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) in Latin America. *Int J Antimicrob Agents.* 2009; 34(4): 304–8.
64. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, et al. Morbidity and cost burden of methicillin-resistant *Staphylococcus aureus* in early onset ventilator-associated pneumonia. *Crit. Care.* 2006; 10: R97. DOI: 10.1186/cc4934:1-7
65. Paul MO, Aderibigbe DA, Sule CZ, Lamikanra A. Antimicrobial sensitivity patterns of hospital and non-hospital strains of *Staphylococcus aureus* isolated from nasal carriers. *J Hyg (Lond).* 1982; 89: 253–6.
66. Ugwu CC, Gomez-Sanz E, Agbo IC, Torres C, and Chah KF. Characterization of mannitol-fermenting methicillin-resistant staphylococci isolated from pigs in Nigeria. *Brazilian Journal of Microbiology* 2015; 46(3): 885-892.
67. Sierra JM, Camoez M, Tubau F, Gasch O, Pujol M, et al. Low prevalence of cfr mediated linezolid resistance among methicillin-resistant *Staphylococcus aureus* in a Spanish Hospital: Case report on linezolid resistance acquired during linezolid therapy. *PLoS ONE.* 2013; 8(3): e59215. DOI: 10.1371/journal.pone.0059215
68. Anonymous. Linezolid. First of a new drug class for gram positive infections. *Drugs Ther Perspect.* 2001; 17(9):1-6. DOI: 10.2165/0004231020011709000001
69. Tsiodras S, Gold HS, Sakoulas G. Linezolid resistance in a clinical isolate of *Staphylococcus aureus*. *Lancet.* 2001; 358:207–8.
70. O'Connor C, Powell J, Finnegan C, O'Gorman A, Barrett S, Hopkins KL, et al. Incidence, management and outcomes of the first cfr-mediated linezolid-resistant *Staphylococcus epidermidis* outbreak in a tertiary referral centre in the republic of Ireland. *The J Hosp Infect.* 2015; 90(4): 316-21.
71. Garcia M, Juan J, Elvira B. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid resistant *Staphylococcus aureus*. *Clin Infect Dis.* 2010; 50(6): 821-5.
72. Potoski BA, Adams J, Clarke L, Shutt K, Linden PK, Baxter C, Pasculle AW, Capitano B, Peleg AY, Szabo D, Paterson DL. Epidemiological Profile of Linezolid-Resistant Coagulase-Negative Staphylococci. *Clin Infect Dis* 2006; 43: 165–71.
73. Abdu A, Lamikanra A. Linezolid and Methicillin Resistances in *S. aureus* Isolated from the Anterior Nares of Apparently Healthy Undergraduates of the Niger Delta University, Nigeria. *Br Microbiol Res J* 2016; 15(6): 1-10.
74. Garcia M, Juan J, Elvira B. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 2010; 50(6): 821-5.
75. Widerstrom M, Wistrom J, Sjostedt A, et al. Coagulase-negative staphylococci: Update on the molecular epidemiology and clinical presentation, with a focus on *Staphylococcus epidermidis* and *Staphylococcus saprophyticus*. *Eur J Clin Microbiol Infect Dis.* 2012; 31: 7-20.
76. Chua K, Laurent F, Coombs G, Gracyson ML, Howden BP. Antimicrobial resistance: Not community-associated methicillin-resistant *Staphylococcus aureus* (CAMRSA)! A clinician's guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. *Clin Infect Dis.* 2011; 52: 99–114.
77. Yalçın B, Selek MB, Bektöre B, Hoşbul T, Özyurt M. Investigation of linezolid resistance in *Staphylococcus epidermidis*: first reported linezolid resistant coagulase negative staphylococcus in Turkey. *Turk J Med Sci* 2014, 44: 1136-38.
78. Yang XJ, Chen Y, Yang Q, Qu TT, Liu LL, Wang HP, Yu YS. Emergence of cfr-harboring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China. *J Med Microbiol* 2013, 62: 845–50.
79. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. *Antimicrob Agents Chemother.* 2012; 56(2): 603-12.
80. Bongiorno D, Campanile F, Mongelli G, et al. DNA methylase modifications and other linezolid resistance mutations in coagulase-negative staphylococci in Italy. *J Antimicrob Chemother.* 2010; 65: 2336–40.
81. Zhu W, Tenover FC, Limor J, et al. Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Eur J Clin Microbiol Infect Dis.* 2007; 26: 161–5.
82. Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. *Mol. Microbiol* 2005; 57(4): 1064-73.
83. Toh, S. M., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J, Mankin, A. S. (2007). Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant *Staphylococcus aureus* resistant to the synthetic antibiotic linezolid. *Mol Microbiol* 64, 1506–14.

FIGURES AND TABLES

Table 1: Age and Sex distribution of the subjects and the isolation (Carriage) Rate of Coagulase negative-Staphylococci colonising anterior nares

Age	Male	Female	No (%) Isolate
15-19	4	6	10(7.35)
20-24	30	49	79(58.09)
25-29	24	13	37(27.21)
30-34	4	3	7(5.15)
35-39	3	0	3(2.21)
Total	65	71	136(100)

Table 2: Antibiotics susceptibility of the isolated CONS species during the studied period

Antibiotics	No (%) CoNS of isolates resistant to antibiotics							Total
	<i>S. epidermidis</i> (n=50)	<i>S. haemolyticus</i> (n=41)	<i>S. saprophyticus</i> (n=13)	<i>S. hominis</i> (n=10)	<i>S. cohnii</i> (n=8)	<i>S. lugdunensis</i> (n=7)	<i>S. xylosus</i> (n=7)	
AMC	20(40)	16(34.02)	3(23.08)	1(10)	1(12.50)	1(14.29)	1(14.29)	43
CEF-MRCoNS	31(62)	25(60.98)	6(46.15)	5(50)	5(62.50)	4(57.14)	4(57.14)	80
CIP	25(50)	20(48.78)	10(76.92)	8(80)	4(50)	4(57.14)	4(57.14)	75
CN	20(40)	10(24.39)	1(7.69)	0(0)	0(0)	0(0)	0(0)	31
COT	45(90)	27(65.87)	7(53.85)	3(30)	4(50)	4(57.14)	4(57.14)	94
ERY	38(76)	41(100)	10(76.92)	7(70)	6(75)	5(71.43)	5(71.43)	112
LZD	26 (52)	20(48.78)	6(46.15)	4(40)	4(50)	3(42.86)	3(42.86)	66
TET	40(80)	36(87.80)	8(61.54)	8(80)	8(100)	4(57.14)	4(57.14)	108

KEY: AMC: Augmentin (30µg), CEF: Cefoxitin (30µg), CIP: Ciprofloxacin (5µg), COT: Co-trimoxazole (25µg), E: Erythromycin (15µg), CN: Gentamycin (30µg), LZD: Linezolid (30µg), and TE: Tetracycline (30µg)




Figure 1: Coagulase negative staphylococci species identified.




Figure 2: Antimicrobial susceptibility profile of CoNS isolates.

KEY: AMC: Augmentin (30µg), CEF: Cefoxitin (30µg), CIP: Ciprofloxacin (5µg), COT: Co-trimoxazole (25µg), E: Erythromycin (15µg), CN: Gentamycin (30µg), LZD: Linezolid (30µg), and TE: Tetracycline (30µg)




Figure 3: The prevalence of multiple antibiotic resistant of the CoNS Isolates

Key: Multiple Resistant $\geq 3 = 112$